This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER+ breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.
See related article by Bago-Horvath et al., p. 5682
Footnotes
Clin Cancer Res 2020;26:5543–5
- Received July 10, 2020.
- Revision received July 20, 2020.
- Accepted August 25, 2020.
- Published first August 28, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
November 2020
Volume 26, Issue 21
Volume 26, Issue 21
The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility
Jump to section
Advertisement